Compounded GLP-1 Laws by State: Semaglutide and Tirzepatide Legality Tracker

Editorial note: This is independent research. It contains no provider rankings and no sponsored placements. The RX Index is affiliate-supported, and one clearly labeled affiliate link appears in the final section for readers who decide they want an FDA-approved option instead. No company paid to be mentioned here. This page is not legal or medical advice.

The short answer

Compounded GLP-1 laws by state don't work the way most websites say they do. No state gives you a simple green or red switch. Federal law decides whether a drug can qualify for compounding under Section 503A or 503B. Your state decides whether the pharmacy, prescriber, and facility are allowed to serve you and can add stricter rules. The federal compounding provisions regulate compounders, not patients—but that still does not make every product or shipment lawful.

That's the honest version. Here's the part almost nobody has told you.

On April 1, 2026, the FDA put a number on one part of the phrase everyone argues about. The agency said that, at this time, it does not intend to take action against a 503A compounder for the “regularly or in inordinate amounts” copy condition when the compounder fills four or fewer prescriptions of that same compounded drug product during a calendar month. That is an enforcement policy. It is not a safe harbor, a new legal limit, a 503B rule, or proof that the product meets every other federal and state condition. Read the FDA policy.

Four. Per month. Per compounded product.

That one number changes the question. It does not erase the rest of the law. This tracker shows what it means for the vial in your fridge—and what it does not.

Is this page for you?

One thing we're giving up

There is no honest color-coded map of compounded GLP-1 laws by state. We're not going to draw you one.

We could. It would get more clicks. Green states, red states, done.

But it would be a lie, and here's why: a state can license a pharmacy to serve its residents while the specific product in that box still fails a federal rule. Two people in the same state, buying the same named drug from two different pharmacies, can be in two different legal situations.

So instead of a fake badge, we show you the four things that actually decide it—and we hand you the official government path to check the pharmacy yourself, for free, in about five minutes.

That's a worse headline. It's a much better answer.

The four things that decide the answer

→ Jump to your state's official sources

Why we built this

The right GLP-1 path isn't the same for everyone. It depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path, and your budget.

The RX Index is the independent GLP-1 decision resource that scores treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

People keep asking the same two questions: Is this actually illegal now? And: If it is, why can I still buy it?

They weren't missing an easy answer. The answer was split across federal policy, state licensing systems, pharmacy-board documents, attorney-general actions, and bill histories. This page assembles those layers in one place.

After you understand the rules, The RX Index's Find My GLP-1 Path tool can narrow the next step by state, budget, insurance, and treatment preference. It is an internal decision tool, not a legal verdict.

What we actually verified

Every legal-status statement below points to the agency, board, legislature, court-linked FDA update, or official enforcement body that issued it. A row without a verified state-specific source says so instead of inventing one.

Is compounded semaglutide legal in my state in 2026?

There is no single yes or no. Whether a compounded GLP-1 may lawfully be made, dispensed, and shipped depends on the exact substance, whether the compounder is operating under Section 503A or 503B, whether the product meets the applicable copy and ingredient rules, the patient-specific facts, and whether the pharmacy and prescriber are authorized to serve the patient's location.

Let's slow that down, because each piece is simple on its own.

Question 1: What exactly is in the vial? Semaglutide base is one thing. Semaglutide sodium is a different active ingredient. Retatrutide and cagrilintide are different again, and FDA says they cannot be used in compounding. If you do not know which substance you have, that is the first thing to find out.

Question 2: Who made it, and under which rule? A 503A pharmacy compounds for an identified patient based on a prescription. A 503B outsourcing facility may make larger batches without first receiving a patient-specific prescription, but it faces a different federal rule set. Neither label means the finished drug is FDA-approved.

Question 3: Why was this product compounded for you? If a 503A product would otherwise be essentially a copy of a commercially available drug, a prescriber can determine and document that a change produces a significant difference for one identified patient. That is not the only condition, but it is the condition mass-market copy claims often skip.

Question 4: Is everyone allowed to serve your location? State rules can apply separately to the dispensing pharmacy, nonresident pharmacy, sterile-compounding operation, telehealth prescriber, and clinic.

Why a company's “we ship to these states” list is not a legal source

This trips up almost everyone.

When a telehealth company says it cannot serve your state, that could mean six different things:

1. Its pharmacy does not hold the needed permit in your state.
2. Its prescribers are not licensed for your location.
3. Its lawyers decided your state is too risky.
4. It changed pharmacy partners and the new one is not set up yet.
5. There is an actual state restriction or enforcement concern.
6. It made a temporary business decision that has nothing to do with a new law.

A missing state does not prove your state banned anything. And a state being on the list does not prove the product meets every federal and state condition.

That is why this tracker sends you to the government's own license path instead of taking a seller's shipping list as law.

Did the FDA ban compounded GLP-1 drugs?

No. The FDA did not issue a nationwide blanket ban on compounded GLP-1 drugs. What changed is that FDA determined the tirzepatide and semaglutide injection shortages were resolved, and the shortage-linked enforcement periods ended in 2025. Compounding can still occur when the applicable federal and state conditions are met. Routine mass copying is a different question.

Here is the corrected sequence from FDA's own page.

Why “not a ban” doesn't mean “everything's fine”

Two wrong answers dominate this topic, and they're wrong in opposite directions.

Wrong answer one: “The FDA banned it.” No. There is no nationwide blanket ban.

Wrong answer two: “It's a 503A pharmacy with a real prescription, so it's automatically legal.” Also no. A pharmacy category and a prescription answer only part of the question.

The truth sits in the middle, and it is not complicated once someone actually explains it.

Why you'll see three different 2026 comment deadlines online

FDA's April 30 press release said comments were due June 29, 2026. The May 1 Federal Register notice used June 30, 2026. FDA then extended the official deadline to July 30, 2026, at 11:59 p.m. ET. See the proposal. See the extension.

If a page still treats a June deadline as current, it missed the extension. That is a useful signal about everything else on it.

What does FDA's four-prescription policy actually mean?

On April 1, 2026, FDA stated that, at this time, it does not intend to take action against a compounder for the 503A condition against making essentially-copy products “regularly or in inordinate amounts” when the compounder fills four or fewer prescriptions of that compounded drug product in a calendar month. The statement is narrow. It is not a safe harbor, not a new legal limit, not a 503B rule, and not proof that every other requirement is met.

This is the most important correction on this page, so let's build it properly.

First, what “essentially a copy” means

FDA says it intends to treat a 503A compounded product as essentially a copy when both are true:

• It has the same active pharmaceutical ingredient as a commercially available drug in the same, similar, or easily substitutable strength; and
• The commercially available drug can be used by the same route of administration, regardless of how it is labeled.

A prescriber can determine and document that a change in the compounded product produces a significant difference for one identified patient. When that exception applies, the product is not treated as essentially a copy under the guidance.

Now, the number

For years, “regularly or in inordinate amounts” was a fog. FDA's April 1 update gave compounders an enforcement line for that one phrase: four or fewer prescriptions of the same compounded drug product during a calendar month.

Read that again with a large telehealth program in mind.

The number is real. The leap from that number to “legal under five” is not.

What this does—and doesn't—mean

What it means: For this one 503A copy condition, FDA says it does not currently intend enforcement when a compounder fills four or fewer prescriptions of the same compounded product in a calendar month.

What it does not mean: Five prescriptions are automatically illegal. Four prescriptions are automatically legal. The ingredients are lawful. The product is not a copy. The prescription is valid. The state permits the shipment. The product is sterile, potent, or safe. None of those conclusions follows from this sentence.

What it means at scale: A program filling more than four prescriptions of the same compounded product in a month cannot sell FDA's narrow enforcement statement as its whole legal answer. It still needs a defensible basis under the applicable pathway. For a 503A product that would otherwise be essentially a copy, that often means a real prescriber determination and documentation of a significant difference for the identified patient.

Not that it is cheaper. Not that it is more convenient. A lower price alone does not create a patient-specific clinical difference.

The one question worth asking your prescriber

You do not need to become a lawyer. Ask this:

“What specific change in this compounded product did you determine makes a significant difference for me, and where is that documented?”

A real answer names the change and the patient-specific benefit: a strength that is not commercially available, an ingredient that must be removed, a route that solves a documented need, or another concrete difference tied to you.

A shrug, “everyone gets this,” or “it's personalized” is not the same answer.

Before you scroll on, do this: open your last prescription label or patient portal and find the legal name of the pharmacy that actually filled it—not the telehealth brand on the box. You will need it in a few minutes.

Does adding B12 or changing the dose make compounded semaglutide legal?

Not automatically. FDA says it may still treat a compounded product that combines semaglutide with another active ingredient such as vitamin B12 as essentially a copy when the products use the same route and the amounts of both active ingredients are within 10% of the strengths of the respective commercially available products. A formulation change matters only when the full legal test is met.

The “with B12” move became popular for an obvious reason. If a product is not essentially a copy, the copy rule does not apply in the same way.

FDA answered that move with a worked example in its April 1, 2026 update. The label can be different while the product still falls inside the copy analysis.

What about custom doses and microdoses?

A strength that is genuinely unavailable commercially can matter. But “slightly different number on the vial” is not a magic word. FDA looks at the same, similar, or easily substitutable strength.

The real question is still: what did the prescriber choose for this identified patient, why does it produce a significant difference, and where is that determination documented?

What about oral or sublingual versions?

A different route can change the copy analysis because FDA asks whether a commercially available drug can be used by the same route. But “oral” or “sublingual” does not end the analysis. The same-API, strength, route, ingredient, prescription, and state conditions still have to be checked.

🚩 Marketing claim to distrust: “Our formula is different, so FDA's rules do not apply to us.” The rules still apply. The question is which rule and whether this product meets it.

503A vs. 503B: what those numbers on your paperwork mean

Section 503A covers traditional compounding for an identified patient based on a prescription. Section 503B covers FDA-registered outsourcing facilities that may compound batches without first receiving patient-specific prescriptions and that face added federal requirements. Neither category produces an FDA-approved finished drug.

You'll see these numbers everywhere in GLP-1 marketing. Here is what they actually tell you.

The mistake almost everyone makes

A 503B registration is not an FDA approval.

Registration places the facility inside the 503B framework and subjects it to federal requirements and inspection. That is meaningful. It still does not tell you that every product from the facility meets every condition, and it does not mean FDA approved the finished drug.

When a company says “our FDA-registered facility,” it is telling you something about the facility. It is not giving you a product approval.

And the mistake in the other direction

503A is not a fake category or a loophole. Traditional compounding is old, legitimate, and necessary. Kids who cannot swallow a pill. People allergic to a dye. A strength that does not exist on a shelf.

The problem is not that 503A exists. It is that “there's a patient's name on it” got treated as if it answered every other question. It doesn't.

Does a valid prescription make compounded semaglutide legal?

A valid patient-specific prescription is required for Section 503A, but it is not sufficient on its own. The substance, ingredients, formulation, copy restriction, patient-specific basis, compounder's practices, prescriber authority, and state authorization are separate gates.

Think about a driver's license.

You need one to drive legally. But having one does not make every trip legal. You can have a valid license and still be speeding, driving an unregistered car, or using a road you are not allowed on.

A prescription works the same way. Necessary. Not sufficient.

What a documented “significant difference” looks like

When a 503A compounder relies on that exception, FDA guidance describes a specific chain:

• The product is for an identified patient.
• The prescriber determines that a change will produce a significant difference for that patient.
• The determination is documented on the prescription.
• The documentation identifies the change and the significant difference it produces.
• A lower price by itself is not the patient-specific clinical change.

That last point hurts, because affordability is the honest reason many people are here. It is a completely understandable reason. It is not, by itself, the documented clinical difference the guidance describes.

What we can't tell you

We cannot look at a marketing page and tell you whether the needed documentation exists in your prescription or chart. Nobody on the internet can.

What we can do is tell you the question exists—which is more than a sales page that skips it will do.

Which GLP-1 substances can't be compounded at all?

FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the one used in approved semaglutide drugs and that it is not aware of a lawful basis for using those salt forms in compounding. FDA separately says retatrutide and cagrilintide cannot be used in compounding under federal law.

This section is short and the stakes are high. Read it even if you skip everything else.

Semaglutide salts

Some products have been sold as semaglutide sodium or semaglutide acetate instead of the semaglutide active ingredient used in approved drugs.

FDA says it lacks information showing that those salt forms have the same chemical and pharmacologic properties and is not aware of a lawful basis for their use in compounding.

What to do: ask the dispensing pharmacy for the exact active ingredient and the source shown in its records. “Pharmaceutical-grade semaglutide” does not answer whether the material is the base form or a salt.

Retatrutide and cagrilintide

FDA states plainly that retatrutide and cagrilintide cannot be used in compounding under federal law. They are not components of FDA-approved drugs and have not been found safe and effective for any condition.

A doctor's prescription does not turn a prohibited compounding substance into a permitted one.

“Research use only” is not a pathway

You'll see peptides sold as “for research purposes” or “not for human consumption,” with dosing instructions attached—which is a strange combination if you think about it for two seconds.

FDA has warned companies selling unapproved semaglutide, tirzepatide, and retatrutide under those labels while directing them to consumers for human use. A research label does not create a retail medical pathway.

A real clinical trial has a sponsor, a protocol, informed consent, an investigator site, and formal oversight. It is not a peptide checkout page with a coupon code.

How does state law change compounded GLP-1 legality?

Federal law sets the conditions a compounder must meet to qualify for the 503A or 503B exemptions. States separately license and discipline pharmacies, prescribers, facilities, and other sellers; they can require more documentation, impose tighter state rules, or enforce ordinary consumer-protection law. A state license cannot waive a federal condition.

Here is the mental model that makes this click.

The three binding state measures that materially change this tracker

California adopted broad compounding regulations effective October 1, 2025. They require the pharmacist to verify and document a clinically significant patient-specific difference before compounding a preparation that is essentially identical to a commercially available drug. The sterile-compounding rules also add component and certificate-of-analysis requirements, including manufacturer information when a certificate comes through a supplier.

Iowa put an explicit copy rule in Iowa Administrative Code 481—552.22. It prohibits essentially-copy compounding unless the approved product is in shortage or the compound is changed to produce a documented clinically significant difference for an individual patient. The filing listed July 16, 2025; a 70-day delay was later lifted on August 11, 2025, and the rule appears in the current code.

Indiana enacted Public Law 136 through SB 282. The final law is broader than GLP-1 drugs. Its compounding provisions cover bulk-substance grade and source, FDA establishment registration, certificates of analysis, testing, records, and documentation from nonresident pharmacies. Those provisions took effect July 1, 2026. Medical-spa registration begins January 1, 2027.

None of those three measures is a blanket state ban on patients receiving all compounded GLP-1 drugs.

The enforcement states

Pennsylvania gives us the clearest number. In October 2025, the State Board of Pharmacy imposed a $1 million civil penalty and probation after finding a pharmacy compounded or processed about 30,000 doses of injectable weight-loss drugs in uninspected facilities.

Ohio issued GLP-1-specific guidance in July 2025 addressing post-shortage copies, ingredient sources and distributors, and substances such as retatrutide and cagrilintide.

Idaho, Utah, and Washington have used or explained ordinary pharmacy, scope-of-practice, facility, sterile-compounding, and dispensing rules in GLP-1-related settings.

In these states, the headline is not always a new statute. It is that ordinary rules are being applied to real conduct.

The states where the Attorney General is the story

Connecticut has used its unfair-trade-practices and unlicensed-pharmacy authority against research-grade direct sellers, misleading claims, and certain clinic or med-spa sales and advertising. Illinois sent cease-and-desist letters to five med spas over misleading GLP-1 language. South Carolina issued a consumer alert focused on misleading claims, research-only products, prescriptions, and licensing.

This is the layer people miss when they check only the pharmacy board. Consumer-protection enforcement can target the marketing and sale even when no new pharmacy regulation was adopted.

Compounded GLP-1 laws by state: 51-jurisdiction tracker

This matrix includes all 50 states and the District of Columbia. It shows every state-specific primary source verified for this version, what that source actually changes, and the official FDA path to the state's pharmacy-license database. A default row does not mean “no state rules.” It means this version does not claim a separate GLP-1-specific state instrument without a primary source in hand.

How to read a row

• State-specific primary source verified means the source was opened and its status was checked.
• Binding means the source is a statute or regulation now in force.
• Guidance, notice, alert, or enforcement is labeled as such. It is not silently upgraded into a law.
• Bill means a proposal. Dead and pending bills are not presented as current law.
• No separate state source verified in this version is a dataset boundary, not a legal conclusion.
• The license link goes to FDA's official state-by-state directory. Search the pharmacy's legal name, not only the telehealth brand.

→ Open FDA's official state pharmacy-license directory

Which state compounded GLP-1 bills passed in 2026?

Among the 2026 measures verified for this tracker, Indiana SB 282 became law. Colorado SB 26-066, Florida SB 860, Kentucky HB 729, and Mississippi SB 2544 died. California AB 1990 remained pending on the Senate Appropriations suspense file as of August 6, 2026. Arizona HB 4036 was introduced, but no enacted law is claimed here.

This table matters because dead bills and early bill versions keep getting repeated as if they are current law.

The California mix-up

Two different California things get treated as one, constantly.

In force right now: the Board of Pharmacy's broad compounding regulations, effective October 1, 2025.

Not law as of August 6, 2026: AB 1990. And the current bill is much narrower than the version introduced earlier in the year. The June 24 amendment stripped the bulk-source, testing, records, inspection, and $1,000-per-dose sections and left advertising and disclosure rules.

So “California banned compounded GLP-1s” is wrong twice. The regulation is not a blanket ban, and the pending bill is not law.

How do I check whether a pharmacy can ship compounded medication to my state?

State requirements are not identical. Many states require an out-of-state pharmacy to hold a nonresident permit before shipping prescription drugs to residents, and some add sterile-compounding, outsourcing-facility, or other approvals. The reliable check is the receiving state's own license database—not a seller's state list.

FDA tells consumers to check the pharmacy through the state board database and not use an online pharmacy that is missing from the relevant database. FDA links every state database here.

Four steps

Step 1 — Get the pharmacy's legal name. Not the brand on the website. Look at the prescription label, shipping box, patient portal, or receipt. The company that sold it and the pharmacy that filled it may be different businesses.

Step 2 — Open the database for the state where the patient is located. Use the FDA directory or the state board link in the tracker.

Step 3 — Search and compare. Check the exact legal name, physical address, status, permit type, expiration date, restrictions, and disciplinary notes. A near match is not a match.

Step 4 — Check the permit type. If the product is an injectable, look for any sterile-compounding, nonresident sterile-compounding, outsourcing-facility, or other approval that the state uses. A general pharmacy license is not always the only credential involved.

What a valid license does not prove

Let's be straight, because this is where a page like this could accidentally oversell.

An active license proves the license shown in the database is active. That's it. It does not prove:

• The specific product meets federal compounding rules.
• The finished product went through FDA premarket approval—it did not.
• The label names the correct substance and strength.
• The dose is right for the patient.
• The shipment stayed inside the required temperature range.
• There is no quality problem outside the public license record.

It is one gate. But it is your gate, and you do not have to take the seller's word for it.

If the pharmacy isn't in the database

Stop and ask before you use the product or pay again.

FDA has reported fraudulent products labeled as compounded semaglutide or tirzepatide where the named pharmacy did not exist, or where a real pharmacy's name was used even though that pharmacy did not make the product. FDA also reports one adverse event associated with a product falsely labeled as compounded tirzepatide from a pharmacy that did not compound it.

That's not a reason to panic. It's a reason to look it up.

What warning signs does FDA list for compounded GLP-1 sellers?

FDA's first telehealth warning sign is a company claiming its compounded drug is the same as an FDA-approved drug. FDA also flags deep discounts, damaged or instruction-free packaging, no licensed-doctor screening and prescription, no clinician available after delivery, label errors, wrong pharmacy addresses, and a pharmacy name that may be fraudulent.

Here is FDA's current list in plain language. Be careful when a company:

1. Claims the compounded drug is the same as an FDA-approved drug.
2. Offers a price that looks too good to be true.
3. Sends medicine that looks different, arrives damaged, or has no instructions.
4. Does not require screening and a prescription from a licensed doctor.
5. Has no licensed doctor available after the medication arrives.
6. Uses misspellings or an incorrect pharmacy address on the label.
7. Lists a pharmacy that may not be real or may not have made the product.

The phrase that should change how you read the page

A compounded drug is not FDA-approved. FDA did not review that finished product for safety, effectiveness, or quality before marketing.

That does not mean every compounded drug is fake or never appropriate. FDA itself says a compounded drug may be appropriate when a patient's medical need cannot be met by an approved drug. It does mean “same as,” “generic Ozempic,” “generic Wegovy,” or “FDA-approved compound” should stop you.

One fair thing in the other direction

FDA's GLP-1 import alert is meant to keep active ingredients with potential quality problems out of the supply chain. But FDA also says the alert does not stop legal importation from compliant manufacturers and does not create new limits on lawful GLP-1 compounding.

Not everything that sounds like a crackdown is a new ban.

The adverse-event numbers, read honestly

As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.

Read those numbers in both directions. FDA says many reported events look like the known adverse effects of the approved drugs, and federal law generally does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events to FDA, so reports are likely incomplete. FDA also says it is not always possible to determine whether the drug caused the reported event or whether other factors contributed.

Association is not proof of causation. Underreporting is not proof of safety. Both facts belong in the same paragraph.

What does “legal in all 50 states” leave out?

The phrase collapses separate questions into one marketing claim. A 503A category, a prescription, and a shipping list each answer a different question. None, by itself, resolves the exact substance, ingredient rule, copy restriction, patient-specific documentation, prescriber authority, pharmacy permit, or product quality.

You'll see this claim a lot. Here is what it quietly skips.

It skips the substance. Semaglutide base and semaglutide sodium are not the same legal question.

It skips the pathway. 503A and 503B do not follow the same bulk-substance and copy rules.

It skips the documentation. No blanket ad can tell you what is documented for one identified patient.

It skips the exact pharmacy. A telehealth company may market nationally while the pharmacy filling one order lacks a needed credential in that patient's state.

It skips the prescriber and clinic. Pharmacy authorization does not establish that the prescriber or facility is properly licensed.

And “available” is not “lawful.” Something being purchasable tells you a business decided to sell it. That's all it tells you.

Seven questions to ask before you pay

A legitimate seller can answer basic questions about the pharmacy, substance, prescriber, prescription, and delivery without deflection. These seven questions cover the facts a patient can check before money changes hands.

Copy these. Paste them into the chat window. Watch what happens.

1. What is the exact legal name and physical address of the pharmacy that will fill this prescription?
2. What is its license or permit number in the state where I will receive it?
3. Is the medication compounded under Section 503A or supplied by a 503B outsourcing facility, and who will dispense it to me?
4. What exact active ingredient and form will appear on the label—semaglutide base, a salt form, tirzepatide, or something else?
5. What specific patient need or product difference is my prescriber documenting for this formulation?
6. Who is the prescriber, and where can I verify the license that covers my location?
7. What are the storage instructions and beyond-use date, and what should I do if it arrives warm, damaged, or different from the last fill?

A good company gives concrete names, numbers, and records. “Our FDA-registered facility” does not answer question one.

→ Save this seven-question checklist

What should I do if my provider stopped shipping compounded GLP-1s to my state?

A shipping change is not automatically a new state law. Providers stop serving states because of pharmacy permits, prescriber licenses, facility rules, formulation concerns, enforcement risk, partner changes, or company policy. Ask the provider to identify the exact cause, then check it against an official source.

If this is why you're here, take a breath. This is usually not what it feels like.

Ask, in writing

Send this:

“Can you tell me whether this change is because of a state law or board rule, the dispensing pharmacy's permit, the prescriber's license, the medication's formulation, an enforcement concern, or company policy? Please name the pharmacy and the official source.”

A real answer names something checkable. “Regulatory changes” by itself is not an answer.

Sort it into one of three problems

Three different problems, three different fixes. Most people burn a week treating all three as one.

Please don't change treatment based only on a web page

Not ours, not anyone's.

If supply is interrupted, talk with the prescriber about continuity, dose timing, storage, and the next safe option. Do not stretch doses, split a vial, combine products, or abruptly change a plan because an article scared you. We can show the legal and verification questions. We cannot see your chart.

If you're not sure which path is left

You've now got the pieces. If you'd rather not assemble them alone, that is what our internal tool is for.

→ Take the free Find My GLP-1 Path quiz for a state-, budget-, insurance-, and treatment-path starting point. No signup. No cost. It does not replace a clinician or legal advice.

What if I want an FDA-approved GLP-1 instead?

FDA-approved drugs go through FDA review for safety, effectiveness, and manufacturing quality before marketing. That removes the 503A and 503B compounding questions on this page. It does not remove prescription, eligibility, insurance, side-effect, or cost questions.

Let's be honest about who this section is for.

Some people read everything above and think: I don't want to check permits and ask about salt forms. I want the path where the finished drug itself went through FDA approval.

That's completely reasonable.

The catch is price. That's a real catch, and we're not going to pretend it isn't. For many people it is the whole reason they looked at a compounded route.

If you want to check the approved path, Ro (affiliate link) currently lists FDA-approved options including Wegovy pill, Foundayo pill, Wegovy pen, and Zepbound KwikPen, with insurance checks for select medications. Ro's public page on August 6, 2026 listed membership at $39 for the first month, then $149 month to month, or $74 per month on a 12-month plan paid upfront. Medication is a separate charge and is not included in the membership fee. Eligibility, product availability, cash prices, manufacturer offers, and insurance coverage can change, so check the live page before paying.

We may earn a commission if you start through that link, at no added cost to you. It does not change this tracker. The affiliate link appears here only after the legal and verification questions are fully answered, and no compounded provider is promoted on this page.

Check insurance before assuming the approved path is impossible. The check is a smaller commitment than changing treatment, and it can tell you whether the real barrier is coverage, prior authorization, cash price, or eligibility.

If an approved option is not realistic for your budget: do not quit here. Go back to the pharmacy-license check, get a concrete answer from the prescriber about the patient-specific basis and formulation, and use the Find My GLP-1 Path tool to see the available paths. A compounded product from an authorized pharmacy, made under a lawful pathway for a real patient need, is a different thing from an anonymous research-peptide website. This page exists to help you tell the difference—not to talk you out of treatment.

What this tracker can and can't tell you

This tracker documents the federal baseline, the state-specific primary sources verified for this version, pending and dead bills, pharmacy-license paths, and the date each row was reviewed. It cannot give legal advice about one transaction, inspect a product, read a patient chart, or determine that a specific prescription complies with every rule.

What it can establish:

• That a cited source exists, who issued it, and when.
• Whether the source is binding law, guidance, an alert, enforcement, or a bill.
• What substances or conduct the source expressly addresses.
• Whether a verified bill is pending, dead, or enacted.
• Where to start the official pharmacy-license check.
• When this version was last reviewed.

What it cannot establish:

• Whether a specific prescription or shipment is lawful.
• Whether a product is pure, potent, sterile, or correctly labeled.
• Whether a company is complying today.
• Whether the medication or dose is right for one patient.
• Whether a regulator has an unpublished investigation.
• Whether a default state row proves that no separate state rule exists.

This page is educational. It is not legal advice or medical advice. The same federal rule can land differently depending on the compounder, product, prescription, prescriber, patient, and state.

How we researched compounded GLP-1 laws in all 50 states

This version uses a source hierarchy and an evidence label. Federal claims come from statute-linked FDA materials and the Federal Register. A state receives a special label only when we opened a state statute, administrative rule, board document, official bill record, attorney-general release, or official enforcement record. All 51 jurisdictions are included for license verification, but a default row is not turned into the unsupported claim that a state has “no rules.”

Source order, highest first:

1. Federal statute, FDA, and the Federal Register.
2. State statute and administrative code.
3. State board of pharmacy or other licensing-board documents.
4. State attorney-general and official enforcement records.
5. Official legislature and bill-status systems.
6. Official court records or FDA updates tied to the court action.
7. Secondary legal or industry sources only to locate a primary document or resolve a broken official interface.
8. Provider pages only for provider-stated price, product, and policy facts—not as legal authority.
9. Forums and social posts only to understand the question people are asking, never as legal evidence.

For the 51-jurisdiction matrix we: include every state and DC; link the official FDA directory that routes to each state's pharmacy database; identify special state material only when the underlying source was opened; separate laws from guidance, enforcement, alerts, and bills; record the verification date; and use a dataset-limit label instead of guessing a negative legal finding.

How we word a negative. We do not write “this state has no GLP-1 rules” unless a competent authority has made that exact conclusion—which is unlikely. We write: no separate GLP-1-specific state source is verified in this version; federal and ordinary state law still apply. Those are different sentences, and only the second is supported by this dataset.

Original evidence on this page. The 51-row source-status matrix, the four-gate patient check, the state-layer taxonomy, the corrected court-adjusted wind-down timeline, and the bill-version comparison were assembled for this version and verified on August 6, 2026. They are the page's contribution; they are not copied from one provider or one legal summary.

Corrections. When a source changes, the version history should name the old statement, the corrected statement, the source, and the date. Old versions should be retained rather than silently replaced.

Frequently asked questions

Is compounded semaglutide illegal now?

No single answer covers every product. The shortage-based period that allowed routine copy compounding ended in 2025. Whether a particular product can qualify for compounding depends on the substance, the 503A or 503B pathway, the copy rules, the prescription and patient-specific facts, and state authorization.

Can I get in trouble for taking compounded semaglutide?

Sections 503A and 503B set conditions for compounders; they do not create a patient-offense rule. This tracker does not give a 51-state criminal-law opinion. The practical reasons to verify the seller are product quality, continuity, cost, and avoiding medicine supplied through an unlawful operation—not an FDA 503A or 503B charge against the patient.

Which states have banned compounded GLP-1s?

This review did not locate a blanket state ban. California and Iowa have binding compounding rules that expressly address copies and patient-specific differences. Indiana enacted broader bulk-substance and compounding requirements. Other states have guidance, enforcement actions, or consumer-protection activity.

Can a 503A pharmacy still compound semaglutide?

Yes, when every applicable 503A and state condition is met. A patient-specific prescription is required but is not enough by itself. FDA's four-prescription statement is an enforcement policy for one 503A copy condition, not a general legality guarantee.

Can a 503B facility compound semaglutide or tirzepatide from bulk?

Semaglutide and tirzepatide are not on FDA's 503B bulks list or drug shortage list. FDA proposed on April 30, 2026 not to add semaglutide, tirzepatide, or liraglutide to the 503B bulks list. Comments closed July 30, 2026, and no final determination was located as of August 6, 2026.

Is compounded tirzepatide treated the same as compounded semaglutide?

The broad framework is similar, but the dates differ. The 503A shortage-related enforcement period for tirzepatide ended March 5, 2025 after a court decision, and the 503B period ended March 19, 2025. For semaglutide, the 503A period ended April 24, 2025 and the 503B period ended May 22, 2025.

Is compounded semaglutide FDA-approved?

No. FDA does not review a compounded drug for safety, effectiveness, or quality before it is marketed.

Does a state pharmacy license prove the product is legal?

No. A license establishes a fact about the pharmacy. It does not prove that a specific product meets federal compounding conditions, contains the stated ingredient, was stored correctly, or is right for the patient.

Can an out-of-state pharmacy ship compounded medication to me?

Only when the pharmacy and transaction meet the receiving state's requirements. Many states require a nonresident pharmacy permit, and some add sterile-compounding or facility approvals. Check the pharmacy's exact legal name in the patient's state database.

Does adding B12 make compounded semaglutide legal?

Not by itself. FDA says a semaglutide-plus-B12 product may still be essentially a copy when the products use the same route and each active ingredient is within 10% of the strength of the respective commercially available product.

Are semaglutide sodium and semaglutide acetate the same as semaglutide base?

No. FDA says the salt forms are different active ingredients from the one used in approved semaglutide drugs and that it is not aware of a lawful basis for using those salt forms in compounding.

Can retatrutide be compounded if a doctor prescribes it?

FDA says retatrutide and cagrilintide cannot be used in compounding under federal law. A prescription does not change that substance-level rule.

Does my GLP-1 telehealth prescription require a video visit?

That is a prescriber-licensing and telehealth question, not just a compounding question. The answer can depend on the prescriber's profession, the patient's location, the drug, and state law. Check the prescriber's license and the patient's state medical or nursing board rules.

What if my pharmacy is not in my state's database?

Do not assume a brand name or a seller's shipping list proves licensure. Ask for the pharmacy's exact legal name, physical address, and state permit number. FDA advises consumers not to use an online pharmacy that is missing from the relevant state database.

How often is this tracker updated?

Federal status is checked weekly while the 503B proposal is unresolved. State-source and license links are checked monthly, with a manual legal-status review at least quarterly and after a new law, rule, order, or enforcement action.

Sources

Federal primary sources

• FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — April 1, 2026, with the corrected 2024–2025 shortage timeline
• FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — content current through June 15, 2026
• FDA, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — April 30, 2026
• Federal Register, 91 FR 23431 — May 1, 2026
• Federal Register extension notice 2026-12937 — June 26, 2026
• FDA, Locate a State-Licensed Online Pharmacy
• FDA, FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients — September 5, 2025

Binding state sources

• California State Board of Pharmacy, Order of Adoption, Compounded Drug Preparations
• Iowa Administrative Code 481—552.22
• Indiana SB 282 / Public Law 136 official bill record

State guidance, alerts, enforcement, and bills

• Alabama Board of Medical Examiners, physician-compounding practice materials
• Arizona HB 4036 introduced text
• California AB 1990 current text and history
• Colorado SB 26-066 official record
• Connecticut Attorney General, May 6, 2026 GLP-1 settlements
• Florida SB 860 official record
• Idaho Board of Pharmacy compounding letter
• Illinois Attorney General GLP-1 consumer alert
• Kansas Board of Pharmacy reports and guidance
• Kentucky Board of Pharmacy compounding FAQ
• Kentucky HB 729 official record
• Mississippi Board of Pharmacy current FDA policy notice
• Mississippi SB 2544 bill record
• Ohio Board of Pharmacy GLP-1 guidance
• Pennsylvania Department of State, Boothwyn Pharmacy enforcement
• South Carolina Attorney General GLP-1 alert
• South Dakota Board of Pharmacy January 2024 notice
• Utah DOPL/Board of Pharmacy May 2024 notice
• Washington Pharmacy Commission semaglutide statement

FDA-approved products named in the final option section

• FDA, Foundayo (orforglipron) approval — April 1, 2026
• FDA-approved Wegovy tablet and injection labeling
• FDA, Zepbound approval for chronic weight management

Provider-stated facts used only in the final option section

• Ro Body pricing and current medication page — checked August 6, 2026

Version history

• v1.1 — August 6, 2026. Corrected FDA's court-adjusted 503A wind-down dates; recast the four-prescription statement as a narrow enforcement policy rather than a safe harbor; added Iowa; corrected Indiana's scope; replaced the incomplete state placeholder with all 51 jurisdictions; corrected the 2026 bill scoreboard and bill versions; removed unsupported competitor and forum claims; corrected state-shipping language; added causation context to adverse-event counts; and separated Ro membership from medication cost.
• v1.0 — August 6, 2026. Initial draft.

How to cite this page

The RX Index Research. “Compounded GLP-1 Laws by State: Semaglutide and Tirzepatide Legality Tracker.” Version 1.1. Last verified August 6, 2026.